PipelinePharma Logo

Generics 2

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Idelalisib manufacturers

2 products found

Filters

Filters

Filters , active

Country of origin : Argentina

Clear all

2 products found

idelalisib

Tablets, film coated 100mg, 150mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina, Brazil, Pakistan, Paraguay, Peru, Uruguay, WHO, PICS
Manufacturer #16112
This company is a leading developer and manufacturer of high-quality pharmaceuticals, specializing in oncology, hematology, transplant cases, and rare diseases. They boast over 360 registered products worldwide and prioritize innovation and continuous improvement in line with rigorous international quality standards. The company has forged partnerships with over 15 international companies and expanded its reach to several Latin American nations. Their product portfolio includes medications for various therapeutic areas such as oncology, hematology, and rare diseases. Key dosage forms include oral, intravenous, and topical preparations. Their commitment to research and development is evident in their active pursuit of new therapies and innovative products like genomic tests for personalized cancer treatment. The company emphasizes patient care and collaborates closely with the medical and scientific communities to achieve its goals.

Want to see all 2 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Idelalisib is a chemotherapic medication used to treat blood cancers, including chronic lymphocytic leukemia, follicular lymphoma, lymphoma, and non-Hodgkin's lymphoma. In the case of chronic lymphocytic leukemia, it is recommended as a second-line treatment and is typically used alongside rituximab. Suppliers of idelalisib market it as 100mg and 150mg oral tablets. First introduced for medical use in 2014 by developer and earliest idelalisib manufacturer Gilead Sciences, the drug has since become available in over 30 countries worldwide. Given that the patent for the drug is still valid, other producers have yet to join the market with their own generic or trade name formulations of idelalisib. Pharmaceutical specialists are welcome to browse through offers of idelalisib tablets from suppliers on our pharmaceutical marketplace, or else seek out further useful medical information about idelalisib online, at the official Zydelig product website.

Popular Searches

Amoxicillin manufacturers Atorvastatin manufacturers Benzocaine manufacturers Calcium carbonate manufacturers Cloperastine fendizoate manufacturers Gabapentin manufacturers Hyaluronic acid manufacturers Ibuprofen manufacturers Ivermectin manufacturers Levothyroxine manufacturers Lisinopril manufacturers Losartan manufacturers Magnesium manufacturers Melatonin manufacturers Metformin manufacturers Methotrexate manufacturers Metoprolol manufacturers Omeprazole manufacturers Paracetamol manufacturers Prednisone manufacturers Pregabalin manufacturers Semaglutide manufacturers Testosterone enanthate manufacturers Vitamin B12 manufacturers

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible